

SPRINGER BRIEFS IN BIOCHEMISTRY AND  
MOLECULAR BIOLOGY

Jessica Nicastro

Shirley Wong

Zahra Khazaei

Peggy Lam

Jonathan Blay

Roderick A. Slavcev

# Bacteriophage Applications— Historical Perspective and Future Potential



Springer

**SpringerBriefs in Biochemistry  
and Molecular Biology**

More information about this series at <http://www.springer.com/series/10196>

Jessica Nicastro · Shirley Wong  
Zahra Khazaei · Peggy Lam  
Jonathan Blay · Roderick A. Slavcev

# Bacteriophage Applications—Historical Perspective and Future Potential

Jessica Nicastro  
School of Pharmacy  
University of Waterloo  
Waterloo, ON  
Canada

Shirley Wong  
School of Pharmacy  
University of Waterloo  
Waterloo, ON  
Canada

Zahra Khazaei  
Western University  
London, ON  
Canada

Peggy Lam  
University of Waterloo  
Waterloo, ON  
Canada

Jonathan Blay  
School of Pharmacy  
University of Waterloo  
Waterloo, ON  
Canada

Roderick A. Slavcev  
School of Pharmacy  
University of Waterloo  
Waterloo, ON  
Canada

ISSN 2211-9353                      ISSN 2211-9361 (electronic)  
SpringerBriefs in Biochemistry and Molecular Biology  
ISBN 978-3-319-45789-5              ISBN 978-3-319-45791-8 (eBook)  
DOI 10.1007/978-3-319-45791-8

Library of Congress Control Number: 2016949574

© The Author(s) 2016

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.

Printed on acid-free paper

This Springer imprint is published by Springer Nature  
The registered company is Springer International Publishing AG  
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

# Contents

<b>1 Overview of Bacteriophage Lifecycles and Applications</b> . . . . .	1
1 Introduction . . . . .	1
2 Phage Infection and Life-Cycle . . . . .	2
2.1 Lytic Phage . . . . .	2
2.2 Temperate Phage . . . . .	3
3 Phage Infection Stages . . . . .	3
3.1 Phage Entry . . . . .	3
3.2 DNA Replication . . . . .	4
3.3 Phage Assembly . . . . .	4
4 Hurdles for Phage-Based Therapeutics . . . . .	5
References . . . . .	6
<b>2 Phage for Biocontrol</b> . . . . .	9
1 Introduction . . . . .	9
2 The Importance of Using Recombinant Phage . . . . .	11
3 Recombinant Phage for the Treatment of Bacterial Infections . . . . .	12
3.1 <i>Escherichia coli</i> ( <i>E. coli</i> ) . . . . .	13
3.2 <i>Staphylococcus aureus</i> ( <i>S. aureus</i> ) . . . . .	14
3.3 <i>Chlamydia trachomatis</i> . . . . .	14
3.4 <i>Pseudomonas aeruginosa</i> ( <i>PA</i> ) . . . . .	15
3.5 <i>Helicobacter pylori</i> ( <i>H. pylori</i> ) . . . . .	16
4 Phage as Drug Delivery Vehicles for the Treatment of Bacterial Infections . . . . .	16
5 Summary . . . . .	17
References . . . . .	17
<b>3 Phage Device Coatings</b> . . . . .	21
1 Introduction . . . . .	21
2 Biofilms on Medical Devices . . . . .	22
2.1 Contributors to Biofilm Resistance . . . . .	23
3 Alternative Medical Coating Devices . . . . .	24

4	Bacteriophage as Bioactive Coatings . . . . .	25
5	Conclusions . . . . .	26
	References . . . . .	27
<b>4</b>	<b>Bacteriophages Functionalized for Gene Delivery and the Targeting of Gene Networks . . . . .</b>	<b>29</b>
1	Introduction to Phage Mediated Delivery of Genetic Material . . . . .	29
2	Bacteriophages as Gene Delivery Vehicles . . . . .	30
3	Phages as Cytotoxic Agents in Eukaryotes . . . . .	33
4	Phages for Delivery to the Central Nervous System . . . . .	34
5	Conclusions . . . . .	34
	References . . . . .	35
<b>5</b>	<b>Phage Probiotics . . . . .</b>	<b>39</b>
1	Introduction: The Gut Microbiota and Probiotics . . . . .	39
2	Roles of the Gut Microbiota and Probiotics . . . . .	41
2.1	Protection Against Pathogens . . . . .	41
2.2	Metabolism . . . . .	41
2.3	Immunomodulation . . . . .	42
2.4	Tissue Development and Maintenance . . . . .	43
3	Bacteriophages in the Gut . . . . .	43
3.1	Phage Population Dynamics . . . . .	44
3.2	Protection Against Pathogens and Immunomodulation . . . . .	45
4	Applications of Phage . . . . .	46
4.1	Lytic Phage Therapy . . . . .	46
4.2	Phage Biotechnology . . . . .	47
5	Conclusions . . . . .	49
	References . . . . .	49
<b>6</b>	<b>Phage for Biodetection . . . . .</b>	<b>59</b>
1	Introduction to Phage-Based Biodetection . . . . .	60
2	Plaque Assays . . . . .	60
2.1	Phage Display for the Improvement of Plaque Assays . . . . .	61
3	Bacteriophage Indicator Organisms (Reporter Phage) . . . . .	62
3.1	Fluorescence-Based Assays . . . . .	62
4	Immobilized Phage Particles as Probes for Bacterial Detection . . . . .	63
5	Conclusions . . . . .	64
	References . . . . .	65
<b>7</b>	<b>Phage-Mediated Immunomodulation . . . . .</b>	<b>69</b>
1	Introduction . . . . .	69
2	Immune Responses to Phage . . . . .	69
2.1	Anti-phage Innate Responses . . . . .	70
2.2	Humoral Immune Responses to Phage (Anti-phage Antibodies) . . . . .	71

- 2.3 Anti-phage Cellular Immunity and the Implications of the Impact of Phage on the Adaptive Responses (T and B Cells). . . . . 72
- 3 Bacteriophage—Based Immune-Pharmaco-Therapies . . . . . 72
  - 3.1 Phage Immunogenicity and Cancer Therapy. . . . . 73
  - 3.2 Bacteriophage Immunotherapy Autoimmune Disorders. . . . . 75
  - 3.3 Bacteriophage Immunotherapy for Drug Addiction. . . . . 76
  - 3.4 Phages and Oxidative Stress . . . . . 76
- 4 Conclusions. . . . . 77
- References. . . . . 77

# Chapter 1

## Overview of Bacteriophage Lifecycles and Applications

### 1 Introduction

Bacteriophages (phages) are well-established bacteria-specific viruses whose discovery is credited to the independent and nearly simultaneous works of Twort (1915) and d'Hérelle (1917) (Summers 1999) in the early 20th century. Each of the researchers characterized phages as the pathogens of bacteria following the hint of much phage-like phenomena from the 19th and 20th centuries. The late 1930s and early 1940s represented the most significant era for phage research and its impact on biological research (Abedon and Thomas-Abedon 2010), including the research by the “Phage Group”. This group included the work of Max Delbrück and other highly notable geneticists, including James Watson and Francis Crick (Abedon 2012a). The group quickly established that phage could be used for the treatment of bacterial infections, since called “phage therapy”, and were so named. “Bacteriophage” translates to “bacteria eaters”.

While phage biology and the study of phage genetics were of interest, it was phage therapy that and its antibacterial potential that was the primary driver for phage research (Hanlon 2007; Summers 2001). Phage therapy however, failed to match the anticipation of its initially envisioned potential, particularly in a time when the phage themselves were poorly characterized, and the approach was thwarted in favour of small molecules in the Western World in the 1950s (Kropinski 2006; Summers 2001).

Although phage-based therapeutics did not meet the expectations of their initial interest, they have played a crucial role in the study of genetics and molecular biology (Henry and Debarbieux 2012), including contributions to the understanding of organisms much more complex than the phage themselves (Campbell 2003; Goodridge 2010). As such, the study of phage may have actually set the stage for its own demise in medicine.